Laboratory Corporation of America Holdings
NYSE:LH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (12.7), the stock would be worth $281.3 (7% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.9 | $263.17 |
0%
|
| 3-Year Average | 12.7 | $281.3 |
+7%
|
| 5-Year Average | 11.4 | $252.12 |
-4%
|
| Industry Average | 12.9 | $285.51 |
+8%
|
| Country Average | 14.4 | $318.08 |
+21%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$28.1B
|
/ |
Jan 2026
$2.2B
|
= |
|
|
$28.1B
|
/ |
Dec 2026
$2.6B
|
= |
|
|
$28.1B
|
/ |
Dec 2027
$2.8B
|
= |
|
|
$28.1B
|
/ |
Dec 2028
$2.9B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.8B USD | 11.9 | 24.7 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
100.2B USD | 14.2 | 55.7 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
68.5B EUR | 7.9 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
73.7B USD | 0 | 12.1 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 9.1 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 9.2 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.1B USD | 11.7 | 21.2 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 5.3 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.5B USD | -30.2 | -27.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 7.2 | 13.9 | |
| US |
|
Brightspring Health Services Inc
NASDAQ:BTSG
|
9.1B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Laboratory Corporation of America Holdings
Glance View
Laboratory Corporation of America Holdings, commonly known as LabCorp, stands as a formidable player in the world of healthcare diagnostics. Emerging from a confluence of scientific innovation and business acumen, LabCorp has carved a niche within the intricate fabric of healthcare services. Since its inception, the company has excelled in offering a comprehensive suite of laboratory-based tests and services, empowering physicians and healthcare providers with critical insights needed for effective patient diagnosis and management. With its headquarters in Burlington, North Carolina, LabCorp operates a vast network of laboratories and patient service centers across the nation, providing services that range from routine blood work to sophisticated genomic testing. The essence of LabCorp’s business model lies in seamless integration across the healthcare continuum, driving both operational efficiency and profitability. Fundamentally, the company generates revenue by performing diagnostic tests on patient specimens, serving hospitals, managed care organizations, physician offices, and governmental agencies. As healthcare systems evolve towards precision medicine, LabCorp has harnessed emerging technologies and innovations like genomic testing to enhance its service offerings. This expansion not only aligns with changing healthcare paradigms but also fortifies its market leadership. By continually investing in research and development, LabCorp keeps its services at the cutting edge, ensuring steady growth and resilience in an ever-changing healthcare landscape.
